Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + dasatinib
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cetuximab + dasatinib is a combination therapy that targets both epidermal growth factor receptor (EGFR) and Src family kinases. Cetuximab is a monoclonal antibody that inhibits EGFR, while dasatinib is a multi-targeted tyrosine kinase inhibitor with primary activity against Src family kinases and ABL. This combination has been investigated in clinical trials for various solid tumors including colorectal cancer, triple-negative breast cancer, and head and neck squamous cell carcinoma. The rationale for combining these agents is based on preclinical evidence suggesting that Src inhibition may help overcome resistance to EGFR inhibitors like cetuximab.
- Other names
- Cetuximab plus DasatinibDasatinib and CetuximabNCT00388427 regimenNCT-00388427 regimenNCT 00388427 regimen
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)SFK (SRC family kinases)
Beyond the preview
Go deeper on cetuximab + dasatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + dasatinib.